On September 1, 2026, cbdMD, Inc. entered into an Asset Purchase Agreement to acquire operating assets of Twinlab Consolidated Holdings, Inc., including brands such as Twinlab, Reserveage, Metabolife, and Alvita Tea, through an assignment for the benefit of creditors proceeding. The consideration includes assuming approximately $1,750,000 in debt owed to Akretive Holdings, LLC and issuing 2,229,805 shares of common stock, representing 19.9% of outstanding shares at execution. The transaction is subject to court approval and customary closing conditions, with completion expected in the first fiscal quarter. Concurrently, effective September 2, 2026, cbdMD amended its Series B Convertible Preferred Stock designations to reduce the conversion price from $1.00 to $0.60 per share. The combined entity projects trailing twelve-month revenues of approximately $30 million as of June 2026, a 40% increase over cbdMD's standalone revenue. cbdMD operates in the consumer wellness industry, building a multi-brand platform across CBD, supplements, and functional health products.